Oxford BioMedica announced that it has voluntarily paused participant recruitment for its gene therapy clinical trials  for wet AMD, Stargardt disease and Usher 1b.

Two national trustees with children affected by retinal disease join the board leadership ranks.

A study conducted by a Foundation-funded research team at the University of Pennsylvania serves as stepping stone to a clinical trial.

World-renowned as an eye expert, and revered as an academic leader, Dr. Ryan was a staunch advocate for retinal research.